Total Payments
$7,618
2024 Payments
$2,271
Companies
43
Transactions
354
Medicare Patients
6,336
Medicare Billing
$815,935
Payment Breakdown by Category
Food & Beverage$7,519 (98.7%)
Education$99.00 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,519 | 353 | 98.7% |
| Education | $99.00 | 1 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,568 | 80 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,176 | 79 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $784.98 | 38 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $371.13 | 14 | $0 (2024) |
| Mylan Specialty L.P. | $320.52 | 10 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $308.28 | 10 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $294.07 | 14 | $0 (2024) |
| Merck Sharp & Dohme LLC | $281.77 | 10 | $0 (2024) |
| ANI Pharmaceuticals, Inc. | $230.01 | 7 | $0 (2024) |
| Ethicon Inc. | $211.72 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,271 | 95 | AstraZeneca Pharmaceuticals LP ($647.69) |
| 2023 | $2,317 | 92 | AstraZeneca Pharmaceuticals LP ($489.78) |
| 2022 | $954.37 | 46 | AstraZeneca Pharmaceuticals LP ($192.56) |
| 2021 | $506.16 | 24 | La Jolla Pharmaceutical Company ($91.12) |
| 2020 | $172.14 | 10 | GlaxoSmithKline, LLC. ($87.59) |
| 2019 | $342.88 | 21 | GlaxoSmithKline, LLC. ($83.43) |
| 2018 | $558.07 | 43 | GlaxoSmithKline, LLC. ($213.14) |
| 2017 | $497.12 | 23 | Boehringer Ingelheim Pharmaceuticals, Inc. ($188.58) |
All Payment Transactions
354 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Respiratory | ||||||
| 12/18/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $30.48 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $27.22 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $29.85 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/09/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: Cardiology | ||||||
| 12/06/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $0.21 | General |
| Category: CRITICAL CARE | ||||||
| 12/04/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: CRITICAL CARE | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $35.49 | General |
| Category: Cardiology | ||||||
| 11/12/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $33.04 | General |
| Category: Inflammation | ||||||
| 11/11/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $68.73 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Respiratory | ||||||
| 11/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: RESPIRATORY | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.03 | General |
| Category: Respiratory | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $31.09 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $21.33 | General |
| Category: RESPIRATORY | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 931 | 1,275 | $223,777 | $109,576 |
| 2022 | 17 | 1,279 | 1,594 | $367,962 | $141,783 |
| 2021 | 18 | 1,838 | 2,556 | $671,820 | $249,994 |
| 2020 | 25 | 2,288 | 3,578 | $860,833 | $314,582 |
Total Patients
6,336
Total Services
9,003
Medicare Billing
$815,935
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 97 | 225 | $94,275 | $38,759 | 41.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 108 | 235 | $37,600 | $22,607 | 60.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 104 | 168 | $27,384 | $16,302 | 59.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 73 | 73 | $18,250 | $9,010 | 49.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 38 | $8,360 | $5,005 | 59.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 51 | $5,610 | $3,414 | 60.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 42 | 42 | $6,888 | $3,359 | 48.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 28 | 29 | $6,090 | $3,054 | 50.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $5,355 | $2,506 | 46.8% |
| 99292 | Critical care, each additional 30 minutes | Facility | 2023 | 13 | 16 | $3,008 | $1,387 | 46.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 17 | $1,904 | $1,026 | 53.9% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 92 | 92 | $1,748 | $845.10 | 48.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 100 | 100 | $2,000 | $790.86 | 39.5% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 107 | 107 | $1,605 | $736.05 | 45.9% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 34 | 34 | $2,320 | $575.85 | 24.8% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 31 | 31 | $1,380 | $200.57 | 14.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 95 | 232 | $111,841 | $40,522 | 36.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 139 | 280 | $57,505 | $23,231 | 40.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 190 | 204 | $41,403 | $19,247 | 46.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 110 | 118 | $34,040 | $14,214 | 41.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 79 | 81 | $33,615 | $12,997 | 38.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 66 | 66 | $19,200 | $7,763 | 40.4% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 98 | 98 | $11,760 | $4,117 | 35.0% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 98 | 98 | $7,840 | $3,984 | 50.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 98 | 98 | $14,700 | $2,914 | 19.8% |
About Dr. Avinash Ramdass, MD
Dr. Avinash Ramdass, MD is a Internal Medicine healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2011. The National Provider Identifier (NPI) number assigned to this provider is 1184911372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Avinash Ramdass, MD has received a total of $7,618 in payments from pharmaceutical and medical device companies, with $2,271 received in 2024. These payments were reported across 354 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($7,519).
As a Medicare-enrolled provider, Ramdass has provided services to 6,336 Medicare beneficiaries, totaling 9,003 services with total Medicare billing of $815,935. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Critical Care Medicine
- Location Jacksonville, FL
- Active Since 07/07/2011
- Last Updated 08/18/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184911372
Products in Payments
- FASENRA (Biological) $634.35
- NUCALA (Biological) $496.93
- DUPIXENT (Biological) $463.24
- TRELEGY ELLIPTA (Drug) $463.03
- OFEV (Drug) $390.96
- TEZSPIRE (Biological) $329.91
- BREZTRI (Drug) $297.36
- ACTHAR (Biological) $265.51
- PURIFIED CORTROPHIN GEL (Drug) $230.01
- Monarch Platform (Device) $211.72
- STIOLTO RESPIMAT (Drug) $194.92
- OPSUMIT (Drug) $193.70
- Yupelri (Drug) $184.84
- ZERBAXA (Drug) $177.02
- GLASSIA (Biological) $162.15
- AIRSUPRA (Drug) $149.63
- CHARTIS CATHETER (Device) $146.47
- UPTRAVI (Drug) $139.39
- TYVASO (Drug) $129.88
- YUPELRI (Drug) $125.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Jacksonville
Siddharth Wayangankar, Md, MD
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Dr. Alan Miller, M.d, M.D
Internal Medicine — Payments: $770,575
Internal Medicine $770,575
Kalina Sanders, M.d, M.D
Internal Medicine — Payments: $626,907
Internal Medicine $626,907
Jose Soto Soto, Md, MD
Internal Medicine — Payments: $576,809
Internal Medicine $576,809
Dr. Jennifer Fulton, Md, MD
Internal Medicine — Payments: $556,016
Internal Medicine $556,016
Dr. Francis Farraye, M.d, M.D
Internal Medicine — Payments: $504,399
Internal Medicine $504,399